Abstract:Abstract Background: Tumor heterogeneity plays a crucial role in disease progression, metastasis and treatment response in lung adenocarcinoma (LUAD). Limited availability of multiple molecularly profiled samples from the same patients poses a challenge to validate models of tumor evolution using real-world data. We investigated genomic changes in a large cohort of patients with clinically directed DNA sequencing of multiple LUAD samples. Methods: We analyzed longitudinal genomic data from 524 patients with at least two LUAD samples sequenced with MSK-IMPACT- a targeted panel that identifies somatic mutations, copy number alterations and gene fusions in 341-505 genes. Our analysis of 1084 tumors (634 primaries [P] and 450 metastases [M]) included 189 matched P-P pairs, 99 M-M pairs and 271 P-M pairs. Pairs were required to share an identical somatic mutation to confirm relatedness. Additional criteria included: excision of primary tumor prior to excision of the metastasis in P-M pairs collected over 90 days apart and collection of M-M pairs from the same anatomic site. Intra-pulmonary metastases were removed from P-P pairs. Results: Tumor mutational burden was correlated in paired specimens from the same patient, irrespectively of P-P (R= 0.75, p<0.001; Spearman correlation), P-M (R=0.72, p<0.001) or M-M (R=0.6, p<0.001) status. Chromosomal instability, measured as the fraction of genome altered by copy number changes (FGA), was also correlated in P-P (R=0.69, p<0.001) and M-M (R=0.57, p<0.001) pairs, but tended to increase in metastases with respect to matched primaries (median 0.58 vs. 0.72, p<0.001; Wilcoxon test). In M-M pairs, changes in FGA differed by anatomic site. Liver pairs had the strongest correlation (n=17 pairs, R=0.86, p <0.01), whereas brain pairs had the weakest (n=35 pairs, R=0.085, p=0.71). Most somatic mutations were shared between paired samples (P-P: 639/1055, 60%, P-M: 1563/2877, 54%, M-M: 550/958, 57%), including those in LUAD drivers- TP53, KRAS, and EGFR. Conversely, most oncogenic copy number alterations - including CDKN2A deletions and MET amplifications - were private to one specimen (P-P: 183/276, 66%, P-M: 880/1148, 76%, M-M: 430/601, 71%), most often in the later sample (P-P: 113/183, 61%, P-M: 636/880, 72%, M-M: 212/430, 49%). Clinically targetable alterations (OncoKB Level 1) tended to be shared by tumor pairs from the same patient (93% shared vs. 6% private in P-P, p<0.01; 85% vs. 14% in P-M, p<0.01; 78% vs. 21% in M-M, p <0.01). Conclusions: In LUAD, metastatic specimens exhibit increased chromosomal instability in relation to their matched primaries. This translates into unique copy number alterations detected only in the metastasis. By contrast, driver mutations - which account for most of the clinically targetable alterations with currently approved FDA drugs - are more often shared between paired samples from the same patient. Citation Format: Brooke Mastrogiacomo, Elizabeth G. Dunne, Cameron N. Fick, John Nguyen, Jairam Hathwar, Manendra Lankadasari, Yuan Liu, Soo-Ryum Yang, Jason Chang, Walid K. Chatila, Nikolaus Schultz, David R. Jones, Francisco Sanchez-Vega. Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2556.

The Mutation Spectrum Revealed by Paired Genome Sequences from a Lung Cancer Patient

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Identification Of Genetic Mutations In Human Lung Cancer By Targeted Sequencing

Genome and Transcriptome Sequencing of Lung Cancers Reveal Diverse Mutational and Splicing Events

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome

The mutagenic forces shaping the genomic landscape of lung cancer in never smokers

Abstract 2536: Mutational Landscape of the Bronchial Epithelium of Individuals at High Risk for Lung Cancer

Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma

Two-round Coamplification at Lower Denaturation Temperature-Pcr (Cold-Pcr)-based Sanger Sequencing Identifies a Novel Spectrum of Low-Level Mutations in Lung Adenocarcinoma.

Frequent Alterations in Cytoskeleton Remodelling Genes in Primary and Metastatic Lung Adenocarcinomas

Targeted Sequencing Reveals Distinct Pathogenic Variants in Chinese Patients with Lung Adenocarcinoma Brain Metastases.

Pathogenic Germline Mutation Profile In Chinese Lung Cancers And Related-Driver Mutation Pattern.

Genomic and evolutionary classification of lung cancer in never smokers

Long-read sequencing unveils novel somatic variants and methylation patterns in the genetic information system of early lung cancer

A Comparative Genomics Analysis of Lung Adenocarcinoma for Chinese Population by Using Panel of Recurrent Mutations

Genomic Heterogeneity of Multiple Synchronous Lung Cancer

Abstract 4664: Massively Parallel Sequencing-Based Analysis of Synchronous Gastric Cancer and Lung Cancer

Genomic features of lung cancer patients harboring germline mutations associated with hereditary cancer syndromes.

Genomic Alteration During Metastasis of Lung Adenocarcinoma

Abstract 2556: Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma